CoChat

Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays

Open access
Buck, Thilo, Wijnholds, Jan · 2020 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 309 of the 334 references it cites were found in a registry or an index; 163 of the 299 sources its claims cite were checked for support.

Abstract

Inherited retinal dystrophies and optic neuropathies cause chronic disabling loss of visual function. The development of recombinant adeno-associated viral vectors (rAAV) gene therapies in all disease fields have been promising, but the translation to the clinic has been slow. The safety and efficacy profiles of rAAV are linked to the dose of applied vectors. DNA changes in the rAAV gene cassette affect potency, the expression pattern (cell-specificity), and the production yield. Here, we present a library of rAAV vectors and elements that provide a workflow to design novel vectors. We first performed a meta-analysis on recombinant rAAV elements in clinical trials (2007–2020) for ocular gene therapies. We analyzed 33 unique rAAV gene cassettes used in 57 ocular clinical trials. The rAAV gene therapy vectors used six unique capsid variants, 16 different promoters, and six unique polyadenylation sequences. Further, we compiled a list of promoters, enhancers, and other sequences used in current rAAV gene cassettes in preclinical studies. Then, we give an update on pro-viral plasmid backbones used to produce the gene therapy vectors, inverted terminal repeats, production yield, and rAAV safety considerations. Finally, we assess rAAV transgene and bioactivity assays applied to cells or organoids in vitro, explants ex vivo, and clinical studies.

Overview

CoChat Summary

TL;DR

This review/meta-analysis catalogs recombinant AAV vector elements used in ocular gene therapy clinical trials (2007–2020) and preclinical assays, analyzing 33 unique rAAV gene cassettes from 57 trials. It provides a workflow/library of capsids, promoters, enhancers, introns, polyadenylation sequences, production considerations, and transgene/bioactivity assay models for designing ocular rAAV vectors.

Key findings

  • The meta-analysis identified 33 unique rAAV gene cassettes used in 57 ocular clinical trials; these used six unique capsid variants, 16 different promoters, and six unique polyadenylation sequences.
  • Five different AAV-RPE65 products were tested in 13 clinical trials, leading to the first retinal gene therapy approved by the FDA in December 2017 and EMA in November 2018 (AAV-hRPE65v2; voretigene neparvovec-rzyl, LUXTURNA).
  • The review compiles vector elements including capsids, ubiquitous and cell-specific promoters, enhancers, introns, WPRE, polyadenylation sequences, pro-viral plasmid backbones, ITRs, and production platforms; it notes rAAV packaging capacity of about 4.5–4.6 kb excluding ITRs, while scAAV reduces capacity to a maximum of 2.5 kb including ITRs.
  • Assay models reviewed include in vitro cell lines, hiPSC-derived RPE, retinal organoids, ex vivo human retina, and in vivo/NHP studies; NHP and human retinal explants matched more closely (correlation r = 0.66–0.67) than mouse/human comparisons (r = 0.24–0.32).

Methods

  • Meta-analysis: clinical trial identifiers were collected from reviews on ocular gene therapy, then searched on clinicaltrials.gov using keywords including AAV, gene therapy, retinitis pigmentosa, RP, Leber congenital amaurosis, LCA, AMD, and CHM, with last search date 01 April 2020; the search was limited to ocular gene therapies and cross-checked against news, reviews, Ph.D. theses, patents, SEC filings, company websites, presentations, and conference abstracts.
  • The 33 unique rAAV ocular gene therapy products were analyzed for prokaryotic plasmid backbone, ITR AAV serotype, enhancers, promoters, introns, cDNA genes, codon optimization, human or other species-related sequences, post-transcriptional stabilizing sequences, polyadenylation sequences, and rAAV production platform; missing information was indicated as “UntoldR” or “?”.
  • The paper also compiles preclinical promoters, enhancers, and other sequences and reviews transgene expression assays and biological activity assays across in vitro, ex vivo, and in vivo models.

Limitations

  • The paper states that many papers on rAAV ocular trials do not sufficiently describe the elements on the plasmid used for viral vector production, including bacterial origin and bacterial selection markers, and that poor description and the vast expanse of rAAV vectors make fair comparison of vector elements very challenging.
  • The paper states that large-scale comparative rAAV element studies are missing in ophthalmology; it also notes that rAAV integration studies in the retina are underrepresented and that almost no rAAV study specifically investigated rAAV integration events.
  • Evident from the text: as a review/meta-analysis, it does not report new primary experimental data, and missing or incomplete source information is marked as “UntoldR” or “?”, indicating reliance on secondary and sometimes incomplete public/company documentation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms21124197

Cites

309 of 309 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 An overview of retinal gene therapy strategies. The effects of the gene variations determine the gene therapy rescue strategy to be applied. Physical DNA delivery includes electroporation, sonoporation, magnetofection, and bioballistic (gene gun) methods. Viruses: AAV, Adeno-associated virus; Ad, Adenovirus; alpha, alphavirus; Epstein-Barr virus (EBV); FV, Foamy virus; HSV, Herpes simplex virus; HIV, Human immunodeficiency virus; VACV, Vaccinia virus. Nucleases: ZNF, Zinc-finger nuclease; TALEN, transcription activator-like effector nuclease; CRISPR/Cas, clustered regulatory interspaced short palindromic repeat (CRISPR)/Cas-based RNA-guided DNA endonuclease. Route of administration: i.cranial, intracranial; i.a., intraarterial; i.cam., intracameral; i.m., intramuscular; i.v., i.t., intrathecal; intravenous (e.g., tail vein or facial vein); i.vit, intravitreal; o.g., oral gavage; r.o., retro-orbital; sub.r, subretinal; sub-T, sub-Tenon; sub.con., sub conjunctiva; s.c., subcutaneous.
Figure 1 An overview of retinal gene therapy strategies. The effects of the gene variations determine the gene therapy rescue strategy to be applied. Physical DNA delivery includes electroporation, sonoporation, magnetofection, and bioballistic (gene gun) methods. Viruses: AAV, Adeno-associated virus; Ad, Adenovirus; alpha, alphavirus; Epstein-Barr virus (EBV); FV, Foamy virus; HSV, Herpes simplex virus; HIV, Human immunodeficiency virus; VACV, Vaccinia virus. Nucleases: ZNF, Zinc-finger nuclease; TALEN, transcription activator-like effector nuclease; CRISPR/Cas, clustered regulatory interspaced short palindromic repeat (CRISPR)/Cas-based RNA-guided DNA endonuclease. Route of administration: i.cranial, intracranial; i.a., intraarterial; i.cam., intracameral; i.m., intramuscular; i.v., i.t., intrathecal; intravenous (e.g., tail vein or facial vein); i.vit, intravitreal; o.g., oral gavage; r.o., retro-orbital; sub.r, subretinal; sub-T, sub-Tenon; sub.con., sub conjunctiva; s.c., subcutaneous.CC BY · PubMed Central
Figure 2 The development of recombinant AAV vectors targeting ocular diseases. (A) Main location (arrow) of frequent gene products (genes indicated) causing retinal diseases (color), and recombinant adeno-associated viral vectors (rAAV)-gene supplementation therapy genes (in clinical trials; underlined genes). (B) Hypothetical rAAV gene cassette and the corresponding plasmid. AAV5, adeno-associated viral vector serotype 5; BC, bipolar cell; Cone, cone photoreceptor; CC, connecting cilium; GC, ganglion cell; GCL, Ganglion Cell Layer; ILM, Inner Limiting Membrane; IPL, Inner Plexiform Layer; ITR, inverted terminal repeat; KanR, kanamycin resistance gene; LCA, Leber congenital amaurosis; MGC, Müller glial cell; ONL, outer nuclear layer; OPL, Outer Plexiform Layer; PRC IS, photoreceptor inner segment; PRC OS, photoreceptor outer segment; polyA, polyadenylation sequence; PRE, post-transcriptional gene regulatory element; RP, retinitis pigmentosa; RPE, retinal pigment epithelium; rod, rod photoreceptor; TSS, transcription start site.
Figure 2 The development of recombinant AAV vectors targeting ocular diseases. (A) Main location (arrow) of frequent gene products (genes indicated) causing retinal diseases (color), and recombinant adeno-associated viral vectors (rAAV)-gene supplementation therapy genes (in clinical trials; underlined genes). (B) Hypothetical rAAV gene cassette and the corresponding plasmid. AAV5, adeno-associated viral vector serotype 5; BC, bipolar cell; Cone, cone photoreceptor; CC, connecting cilium; GC, ganglion cell; GCL, Ganglion Cell Layer; ILM, Inner Limiting Membrane; IPL, Inner Plexiform Layer; ITR, inverted terminal repeat; KanR, kanamycin resistance gene; LCA, Leber congenital amaurosis; MGC, Müller glial cell; ONL, outer nuclear layer; OPL, Outer Plexiform Layer; PRC IS, photoreceptor inner segment; PRC OS, photoreceptor outer segment; polyA, polyadenylation sequence; PRE, post-transcriptional gene regulatory element; RP, retinitis pigmentosa; RPE, retinal pigment epithelium; rod, rod photoreceptor; TSS, transcription start site.CC BY · PubMed Central
Figure 3 Development of rAAV therapies over the years. (A) Unique rAAV capsids usage over time (%; y-axis left) and unique rAAV treatments (genes) in clinical trials (number; y-axis right; Total = 33 of 57 rAAV total clinical trials for the retina). (B) Unique rAAV treatments (genes) and their promoters for the retina (2007–2013 vs. 2013–2019). (C) Unique rAAV treatments (genes) and their polyadenylation sequences in the retina (total = 28). (D) Sponsors with unique rAAV, Lentiviral vector, and AON treatments in clinical trials for the retina/choroid (genes; %; Total = 38). bGH, bovine growth hormone; CAG/CMV, ubiquitous promoters; late SV40, late Simian Virus; MG, Müller glial cell; RPE, retinal pigment epithelium; PRC-BiP, photoreceptor-bipolar-specific promoter; PRC, photoreceptor-specific promoter; rb β-globin, rabbit β-globin polyadenylation sequence.
Figure 3 Development of rAAV therapies over the years. (A) Unique rAAV capsids usage over time (%; y-axis left) and unique rAAV treatments (genes) in clinical trials (number; y-axis right; Total = 33 of 57 rAAV total clinical trials for the retina). (B) Unique rAAV treatments (genes) and their promoters for the retina (2007–2013 vs. 2013–2019). (C) Unique rAAV treatments (genes) and their polyadenylation sequences in the retina (total = 28). (D) Sponsors with unique rAAV, Lentiviral vector, and AON treatments in clinical trials for the retina/choroid (genes; %; Total = 38). bGH, bovine growth hormone; CAG/CMV, ubiquitous promoters; late SV40, late Simian Virus; MG, Müller glial cell; RPE, retinal pigment epithelium; PRC-BiP, photoreceptor-bipolar-specific promoter; PRC, photoreceptor-specific promoter; rb β-globin, rabbit β-globin polyadenylation sequence.CC BY · PubMed Central
Figure 4 How to assess Inverted Terminal Repeats (ITRs) of rAAV and how they allow concatemerization. (A) Restriction enzyme sites in the AAV serotype 2 ITR in the flop configuration. RBE’/RBE binds Rep68 (RBE, Rep-binding element) and initiates the Rep helicase. The Rep helicase nicks the trs (terminal resolution site). Restriction enzyme recognition site indicated in blue and the actual cut in red. Figure adapted from [238]. (B) ITR structure in the nucleus after second-strand DNA synthesis in dividing cells favoring homologous recombination. Most rAAV-vectors form episomal concatemeric circular double-stranded DNA.
Figure 4 How to assess Inverted Terminal Repeats (ITRs) of rAAV and how they allow concatemerization. (A) Restriction enzyme sites in the AAV serotype 2 ITR in the flop configuration. RBE’/RBE binds Rep68 (RBE, Rep-binding element) and initiates the Rep helicase. The Rep helicase nicks the trs (terminal resolution site). Restriction enzyme recognition site indicated in blue and the actual cut in red. Figure adapted from [238]. (B) ITR structure in the nucleus after second-strand DNA synthesis in dividing cells favoring homologous recombination. Most rAAV-vectors form episomal concatemeric circular double-stranded DNA.CC BY · PubMed Central
Figure 5 A hypothetical model of the spread of rAAV capsids (serotypes 1, 2, 5 8, and 9) after intravitreal or subretinal injection in disease or non-disease mouse retinas in vivo based on the studies [99,294,304,306,308,309]. RPE, retinal pigment epithelium; OLM, outer limiting membrane, ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; GCL, ganglion cell layer; ILM, Inner Limiting Membrane.
Figure 5 A hypothetical model of the spread of rAAV capsids (serotypes 1, 2, 5 8, and 9) after intravitreal or subretinal injection in disease or non-disease mouse retinas in vivo based on the studies [99,294,304,306,308,309]. RPE, retinal pigment epithelium; OLM, outer limiting membrane, ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; GCL, ganglion cell layer; ILM, Inner Limiting Membrane.CC BY · PubMed Central
Figure 6 Qualitative assessment of biological relevance and time of assay for retina-specific rAAV potency assay models. Abbreviations: hiPSC, human induced pluripotent stem cell; NHP, non-human primates; RPE, retinal pigment epithelium.
Figure 6 Qualitative assessment of biological relevance and time of assay for retina-specific rAAV potency assay models. Abbreviations: hiPSC, human induced pluripotent stem cell; NHP, non-human primates; RPE, retinal pigment epithelium.CC BY · PubMed Central

Verification

Claims the paper makes

109 Valid · 57 Not valid · 98 Not checked · 102 Own results and interpretations

203 more claims · 84 with their cited sources checked

Create a free account to see all 366 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 107
  • Probably not a substantial claim. 78

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 309 references

Research works printed but not linked: 5

  1. Fahim, A.T., Daiger, S.P., and Weleber, R.G. (2017, January 19). Nonsyndromic Retinitis Pigmentosa Overview, Available online: http://www.ncbi.nlm.nih.gov/pubmed/20301590.
  2. Kremer, J.M.J., Keunen, J.E.E., and van Wijk, H.A.R. (2018). Gene therapy using miniUSH2A genes improves visual function in a zebrafish ush2a knock-out model. Towards gene therapy for USH2A-associated retinitis pigmentosa. ~Fishing for answers~ [Doctoral Thesis], Radboud University Nijmegen.
  3. 2017, The pathway from genes to gene therapy in glaucoma: A review of possibilities for using genes as glaucoma drugs, Asia-Pacific J. Ophthalmol., 6, 80
  4. Ceiler, J., Afzal, S., Leuchs, B., Fronza, R., Lulay, C., Büning, H., Schmidt, M., and Gil-Farina, I. (2017, January 10). Wild-Type and Recombinant AAV Integration in Human Cardiomyocytes: Focus on Mitochondrial Genome. Proceedings of the AAV Vector Biology, Available online: https://www.researchgate.net/publication/316699961_Wild-Type_and_Recombinant_AAV_Integration_in_Human_Cardiomyocytes_Focus_on_Mitochondrial_Genome.
  5. Couto, 2016, Poster C0048 ARVO: Potency Assay for AAV Vector Encoding Retinal Pigment Epithelial 65 Protein, Investig. Ophthalmol. Vis. Sci., 57, 1

Cited by

See all 95

Metadata

Authors
Buck, T., & Wijnholds, J.
Affiliations
  • Leiden University Medical Center (NL)
  • Netherlands Institute for Neuroscience (NL)
Corresponding author
Wijnholds, Jan
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-06-12
Volume
21
Issue
12
Pages
4197
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3035416273
Cited by
92
References
334
Citations by year
2026: 10 · 2025: 17 · 2024: 17 · 2023: 15 · 2022: 16 · 2021: 15 · 2020: 2
FWCI
1.71
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (publishedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (submittedVersion, other-oa)
Funders
  • Foundation Fighting Blindness (TA-GT-0715-0665-LUMC)
  • The Netherlands Organization for Health Research and Development (43200004)
  • Million Dollar Bike Ride Grant Program (MDBR-19-131-CRB1, MDBR-20-112-CRB1)
  • Dutch blindness funds (Uitzicht 2013-13)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
adeno-associated virus vectors, ocular gene therapy, inherited retinal disease, optic neuropathy, promoter, inverted terminal repeats, biological activity assay, retinal organoids, clinical trials
MeSH terms
Dependovirus, Clinical Trials as Topic, Genetic Vectors, Optic Nerve Diseases, Promoter Regions, Genetic, Genetic Therapy, Treatment Outcome, Polyadenylation, Capsid Proteins, Retinal Dystrophies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays. https://app.cochat.ai/papers/10.3390/ijms21124197
The paper
Buck, T., & Wijnholds, J. (2020). Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21124197

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.